AGENDA 2025
The Agenda on this page relates to the 9th annual US Summit which was held in Washington D.C., on May 19th 2025. We are currently researching the 2026 Summit which will be the 10th annual meeting.
We thank past and present speakers who offer their valuable time and insights to help develop a thought-provoking and informative program. I hope you can join us in May.
If you cannot join us in Washington but would like to participate virtually, the Summit will be live-streamed according to the agenda (US EST). Individual videos of speaker presentations and panel discussions will be added to the Summit app within 48 hours of the live event, allowing delegates to watch or re-watch on demand later. The app will be available to all registered delegates for 3 months following the event.
NICOTINE, TOBACCO & GOVERNMENT POLICY
8:15 am - 8:20 am
Welcome from the AM Chair
Chair
Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
8:20 am - 8:35 am
OPENING KEYNOTE: Responsible dissemination: Exploring the role of public health organizations regarding tobacco harm reduction
Public health organizations, both governmental and non-profit, have extraordinarily important roles disseminating - to the public, influencers, healthcare providers, policy makers and others – the most accurate, science-driven information to improve public health. Providing the most accurate and thorough information is an exceptional challenge because the scientific consensus is not always clear. At the same time, this challenge could also be influenced by a variety of other factors, including distrust of companies (nicotine, tobacco and perhaps any company), conscious or unconscious bias regarding harm reduction, the perceived need to meet funder requirements, etc. This presentation will discuss examples and challenges related to accurate dissemination of information by public health organizations and begin to explore ways to improve responsible dissemination of harm reduction information.
Speaker
Prof Scott J. Leischow Research Professor, College of Health Solutions - Arizona State University`
8:35 am - 8:50 am
Is nicotine the new smoking, or the end of smoking? Lessons from New Zealand
New Zealand has some of the most liberal vaping laws in the world, and the rapid rise in vape use has correlated with unprecedented declines in smoking since 2018. Overall nicotine use is up, but the way New Zealander’s use it have transformed. Less than 6.9% of adults now smoke daily. New Zealand has a goal to be smokefree by the end of 2025, meaning less than 5% adult daily smoking. The rapid declines in smoking in recent years mean we have surpassed this goal for young people, the least deprived and will likely achieve it for women and European New Zealanders. Youth smoking is almost a thing of the past, and rates of decline have been especially rapid for Māori.
A change in government saw New Zealand abandon laws to denicotinise cigarettes, ban most combustible sales and mandate a smokefree generation. Instead, the new government is favouring a harm reduction approach, increasing access to non-combusted nicotine.
This talk will examine progress to date, whether harm reduction is a feasible endgame strategy for smoking in New Zealand, and whether it can overcome political tensions, outrage and headlines about youth vaping, and a growing public health movement against nicotine and addiction.
Speaker
Ben Youdan Director - ASH New Zealand
8:50 am - 9:05 am
“Stop the Swap”: A new hazard in tobacco control
Health professionals in the UK and New Zealand are engaging with non-therapeutic products for therapeutic purposes. High-quality independent reviews find high certainty evidence that vapes are as effective for smoking cessation as the most effective pharmacotherapies, with similarly low rates of adverse events, but with greater user acceptability. Unlike other approaches, they do not require high levels of motivation. Indeed, smokers who vape daily have much higher rates of smoking cessation regardless of intention to quit. Consequently, “swap to stop” programmes - programmes that provide priority groups of smokers directly with approved devices - offer a unique opportunity, especially for the most disadvantaged and dependent smokers.
However, the factors that drive use among adult smokers - affordability, accessibility and appeal - also drive use among youth and so are the growing target of public health policies. Around the world, many jurisdictions are adopting policies intended to “stop the start”, reducing uptake among youth.
When these policies also “stop the swap”, they can undermine smoking cessation and increase smoking and its harms. Like it or not, policy makers must recognise and manage these trade-offs or risk worsening health outcomes and inequalities.
Session Responder
Martin Dockrell Former Tobacco Control Programme Lead - (Retired) The Office of Health Improvement and Disparities (OHID), UK
9:05 am - 9:20 am
Getting e-cigarettes into clinicians’ tobacco treatment tool kit: Progress, barriers, and practical suggestion
Evidence has consistently supported that e-cigarettes are an effective tool to help adults stop smoking and are substantially less harmful than continuing to smoke. Yet clinicians and patients alike are often skeptical and adverse to recommending or trying e-cigarettes. Two distinct barriers are contributing to this stalemate. First, there is a misperception of absolute and relative risks between e-cigarettes and combustible tobacco products. Second, because no e-cigarette has received, or is likely to receive, a medicinal approval under the “safe and effective” standard, these are not a type of traditional quit smoking product that clinicians are accustomed to recommending. Although a handful of products have been approved as "appropriate for the protection of public health" under the existing PMTA process, there is little education to differentiate these products from a much larger unregulated market which offers considerably more choice (specifically on flavors, which has proved important in trials), but would be next to impossible for medical clinicians to recommend. Recognizing the urgent need for clinicians to support patients in their efforts to quit smoking, the question becomes whether and how to integrate non-medicinal e-cigarettes into the tobacco treatment toolkit and what regulatory pathway can be found to instil confidence for clinicians and patients alike, including safety, accessibility and acceptability.
Speaker
Dr. Nancy A. Rigotti, MD Professor of Medicine, Harvard Medical School - Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston
9:20 am - 9:50 am
The Opening Conversation: Can the Trump Administration resurrect the FDA’s 2017 Comprehensive Plan in 2025?
FDA’s comprehensive plan for the regulation of tobacco and nicotine was announced in 2017 during the first Trump Administration. Events in 2018 overtook efforts to implement that plan. Former Commissioner Gottlieb’s resignation in 2019 was the final nail in the coffin of the 2017 plan. Do the critical components of the 2017 plan stand the test of time? If so, can the plan be resurrected by the Trump Administration in 2025? To what degree would such efforts be undermined by the behavior of the current Administration and the ongoing dispute in U.S. tobacco control and public health circles regarding the application of harm reduction principles to regulatory policy? Retired CTP Center Director Mitch Zeller will attempt to address these simple issues. Let’s see if he can pull it off.
Chair
Prof Thomas J. Glynn, PhD Adjunct Lecturer - Stanford Prevention Research Centre, Stanford University School of Medicine
Speaker
Mitch Zeller J.D Retired Director, Center for Tobacco Products (CTP) - The Food & Drug Administration (FDA)
9:50 am - 10:15 am
Panel Discussion and Q&A
Nicotine, Tobacco & Government Policy
- Has the communication of scientific evidence confused the public
- Can regulation of a consumer nicotine market satisfy tobacco control, or is prohibition of anything other than a medically licensed product the only acceptable option for some.
- Is a medically licensed e-cigarette possible or likely?
- If people use a non-medicinal e-cigarette to stop or replace smoking, is this “therapeutic” or “recreational” use?
Chair
- Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
Speakers
- Mitch Zeller J.D Retired Director, Center for Tobacco Products (CTP) - The Food & Drug Administration (FDA)
- Ben Youdan Director - ASH New Zealand
- Martin Dockrell Former Tobacco Control Programme Lead - (Retired) The Office of Health Improvement and Disparities (OHID), UK
- Dr. Nancy A. Rigotti, MD Professor of Medicine, Harvard Medical School - Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston
- Prof Scott J. Leischow Research Professor, College of Health Solutions - Arizona State University`
10:15 am - 10:35 am
AM REFRESHMENT BREAK
INDUSTRY, NICOTINE & SOCIETY
10:35 am - 10:50 am
Current policy disasters – can the future still be a success?
In this session, Tim Phillips will focus on the latest consumer and industry data trends in the US, while also discussing the stratospheric growth of illicit markets worldwide. This specifically poses a major risk to the sector's reputation and has implications for how these products could be regulated.
Speaker
Tim Phillips Managing Director - ECigIntelligence
10:50 am - 11:05 am
Maximizing public health in the context of product standards on combusted products
To accelerate the reduction in tobacco-caused mortality and morbidity, standards on combusted tobacco to make them non-addictive and/or non-appealing should be considered for implementation. This goal can be achieved by dramatically reducing the nicotine content in cigarettes, banning flavors or all additives, and/or banning filter ventilation or filters altogether. At the same time, smoking cessation products need to be made easily accessible and affordable. But for those who smoke and are not interested in using medicinal products or quitting nicotine use, appealing non-combusted tobacco or nicotine products must also be available. This presentation will highlight what we need when a product standard for combusted products is implemented to facilitate intended consequences and minimize unintended consequences.
Speaker
Prof Dorothy K. Hatsukami Professor, Department of Psychiatry and Behavioral Sciences - University of Minnesota
11:05 am - 11:20 am
E-cigarette regulation and mortality
This presentation evaluates the public health consequences following the judicial exemption of e-cigarettes from U.S. drug regulation in 2010. For approximately six years, e-cigarettes occupied a regulatory vacuum until being classified as tobacco products subject to FDA regulation under the Tobacco Control Act in 2016. During this period of limited oversight, there was substantial innovation in e-cigarette technologies, as evidenced by increased patent applications. The session explores how this innovation impacted public health, revealing that—contrary to historical trends in tobacco industry innovation—e-cigarettes significantly reduced cigarette smoking rates and associated mortality. Using a comparative analysis across demographic groups, the research demonstrates greater smoking declines and mortality reductions among groups initially characterized by high smoking prevalence, a pattern not observed following the introduction of nicotine replacement therapy as a regulated drug in 1984. Overall, e-cigarettes are estimated to have saved approximately 677,000 life-years between 2011 and 2019, roughly one-third of the benefit attributed to early HIV/AIDS treatments up to the year 2000. The presentation concludes by discussing how insights from this unique regulatory case can inform current and future approaches to e-cigarette regulation under the Tobacco Control Act.
Speakers
Prof Michael Pesko Professor, J. Rhoads Foster Chair of Economics - University of Missouri
Christian Matthew Saenz Doctoral Candidate, Department of Economics at the Andrew Young School of Policy Studies - Georgia State University
11:20 am - 11:35 am
Industry’s attitude toward potential reforms of FDA’s nicotine and tobacco policy
Under new leadership at HHS and FDA, dramatic changes appear to be on the way for U.S. nicotine and tobacco policy. Though the pace and scope of change within FDA and CTP are unprecedented and controversial, it should be recalled that the nicotine vaping marketplace was uniformly seen to be in disarray by all stakeholders, with some 90% of available products being illicit. Is it possible to achieve a new nicotine and tobacco policy that is capable of producing consensus support – recognizing that there is a need to be mindful of the different interests and concerns of legacy tobacco companies, tobacco control groups, small manufacturers, and consumers? Given that prior landmark tobacco control measures were enabled by an agreement between tobacco control and industry actors—most notably the Master Settlement Agreement and the Tobacco Control Act itself—it is essential to analyze the likely perspectives of the various stakeholders. The goal would be to determine the potential for overlapping support for elements of a reformed policy and thereby identify the "art of the possible” when it comes to nicotine and tobacco policy reform.
Speaker
Jeff Weiss Writer & Commentator, Chief Engagement Officer - DF Medical Ventures
11:35 am - 11:50 am
Maximizing the impact of non-combusted tobacco products for harm reduction: the right products for the right people
Several rigorous clinical trials have found that e-cigarettes can help people stop smoking and appear to do so better than nicotine replacement therapy. It is now time to consider how we can maximize the benefits of harm reduction. Dr. Smith will share recent secondary analyses of a large randomized clinical trial of e-cigarettes in which we assess the impact of e-cigarette flavoring and a variety of baseline demographic and smoking variables on key outcomes. She will also discuss the utility of a harm reduction approach for different populations.
Speaker
Dr Tracy Smith, PhD Associate Professor, Department of Psychiatry and Behavioral Sciences - Medical University of South Carolina (MUSC)
11:50 am - 12:05 pm
Fixing the broken and lawless tobacco and nicotine market
This presentation will outline the radical and non-incremental reform overhaul that is necessary to fix America's broken and increasingly lawless tobacco and nicotine market. Marginal changes will not cut it, but is a deeper reform agenda possible under the existing Tobacco Control Act. It is not only possible but necessary and urgent. In my view, the much-admired 2017 Comprehensive Plan is not for purpose and never was; the incoming FDA leadership needs a new 2025 Comprehensive Plan based on realistic, deliverable policies and an unswerving commitment to reduce disease and death as deeply and rapidly as possible.
Speaker
Clive Bates Director - Counterfactual Consulting Ltd
12:05 pm - 12:35 pm
Panel Discussion and Q&A
Industry, Society & Nicotine
- Are alternative nicotine products fundamental to delivering on a potential VLNC policy
- Is increased population nicotine use an acceptable cost for ending smoking
- Did the PMTA create a black market, or has the implementation failed to deliver on its potential
- What would a well-regulated nicotine market look like? Can it reduce demand for some and meet supply for others simultaneously?
- Is nicotine use in society inevitable, and if so, how much and by whom
Chair
- Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
Speakers
- Tim Phillips Managing Director - ECigIntelligence
- Prof Dorothy K. Hatsukami Professor, Department of Psychiatry and Behavioral Sciences - University of Minnesota
- Prof Michael Pesko Professor, J. Rhoads Foster Chair of Economics - University of Missouri
- Jeff Weiss Writer & Commentator, Chief Engagement Officer - DF Medical Ventures
- Dr Tracy Smith, PhD Associate Professor, Department of Psychiatry and Behavioral Sciences - Medical University of South Carolina (MUSC)
- Clive Bates Director - Counterfactual Consulting Ltd
12:35 pm - 1:35 pm
LUNCH
THR, CESSATION & HEALTH
1:35 pm - 1:40 pm
Welcome & Introductions from the Summit PM Chair
Chair
- Prof Thomas J. Glynn, PhD Adjunct Lecturer - Stanford Prevention Research Centre, Stanford University School of Medicine
1:40 pm - 1:55 pm
What we can and cannot conclude about the harms of vaping – the good, the bad and the ugly of existing research and discourse on the risks of e-cigarette use
This presentation will provide an overview of the latest research to assess the long-term health effects of vaping, both in terms of relative (compared with smoking) and absolute risks (compared with not using anything at all). It will also briefly cover other novel nicotine delivery devices that are becoming more popular, specifically nicotine pouches, and how these compare with e-cigarettes. The talk will examine examples of frequent misrepresentations of findings, either underplaying or overplaying the consequences of e-cigarette use, and summarise what we can reasonably claim about the risks of vaping at this point in time, given the existing evidence. It will conclude by highlighting important gaps in the literature and will provide suggestions for what future research should focus on in order to improve our understanding of the population impact of vaping
Speaker
Prof Lion Shahab Professor of Health Psychology & Head of Research - Department of Behavioural Science and Health, University College London (UCL)
1:55 pm - 2:10 pm
The benefits and risks of oral nicotine pouches: Implications for public health
The sale of non-tobacco oral products, particularly oral nicotine pouches, has recently increased in the U.S. and around the world, particularly among young adults. Such pouches provide the pharmacological effects of relatively pure nicotine without the risks of combusted or non-combusted tobacco products. The more important potential benefit for public health would be if people who smoke switched to ONP. The effectiveness of ONP for smoking cessation is not yet established, but clinical trials are ongoing. Other benefits reported by users of ONP include pleasure, mood modulation, cognitive enhancement (use at work or when studying), sports (golf, baseball – to promote concentration and focus), and partying (along with alcohol in bars where smoking is not permitted). It is clear that many people like to use nicotine and would like to continue its use in an ongoing way. The primary established risk of ONP is addictive use. In Scandinavia, compulsive daily use of snus is common among adolescent males, and this pattern is also observed in some U.S. users. There will likely be some risk of nicotine pouch use during pregnancy. Other potential harms of nicotine, including cardiovascular disease, impairment of adolescent brain development, oral disease, infectious disease risk and cancer, will be discussed, based on what is known about the harms of nicotine in Swedish snus. The overall impact of ONP on public health in the short term will likely depend on the balance of benefit in the promotion of smoking cessation vs the risks of addictive use, particularly among youth. Whether there will be public acceptance of ONP use once smoking is eliminated, based on the perceived cognitive and other benefits, remains to be seen.
Speaker
Prof Neal L. Benowitz MD Professor of Medicine Emeritus (Active) - University of California, San Franciso
2:10 pm - 2:25 pm
Vaping to quit smoking, not smoking to quit vaping: The importance of sticking to the facts
The use of e-cigarettes to quit smoking has been politicized since the get-go. Vaping cessation is now also becoming politicized, with potentially harmful consequences. In this talk, I’ll discuss the importance of generating and communicating reliable and accurate information on both. I’ll draw on evidence from a recent overview of systematic reviews as well as two recent Cochrane living systematic reviews, one on e-cigarettes for smoking cessation and the other on interventions for quitting vaping. I’ll conclude by proposing a set of evidence-based statements that, hopefully, most will agree with, regardless of their stance on vaping and smoking.
Speaker
Dr Jamie Hartmann-Boyce Assistant Professor in Health Promotion and Policy - University of Massachusetts Amherst
2:25 pm - 2:40 pm
Challenges in communication about vaping and smoking cessation
In the absence of clear guidance from most major societies, what is the role of a clinician in counseling someone who smokes cigarettes about switching to e-cigarettes? What about in counseling someone to stop using e-cigarettes? How do you even begin to have the discussion with someone when the majority of both the public and clinicians believe that e-cigarettes are as least as harmful as combustible cigarettes? While there is compelling evidence that e-cigarettes are more effective than nicotine replacement at helping people quit smoking, there is very little guidance about how to actually have the conversation. This presentation will focus on the key challenges in communication with people about vaping and smoking cessation. It will discuss what literature there is, as well as provide suggestions for what to do in lieu of clear scientific and policy recommendations.
Speaker
Prof Scott Sherman Professor of Population Health, Medicine and Psychiatry - NYU Grossman School of Medicine
2:40 pm - 2:55 pm
Thinking through a paradigm for evaluating novel nicotine products: What have we learned and what do we need to know?
During this talk, Dr. Piper will review the challenges to the scientific community that arose when e-cigarettes came on the market and what we have learned about addressing the critical scientific questions needed to inform public health, clinical care, and regulation. She will discuss the potential benefits of developing and implementing a paradigm for investigating novel nicotine products to address these questions in a timely way.
Speaker
Prof Megan Piper, PhD Professor, Division of General Internal Medicine, Department of Medicine - University of Wisconsin Madison
2:55 pm - 3:25 pm
Panel Discussion and Q&A
THR, Cessation & Health
- Does the focus on vaping cessation come at the expense of smoking cessation
- Dual use has been a perennial battleground. Is this a failure of the product, regulation or public health communication
- Will nicotine pouches assuage safety concerns, and could or will this change the conversation on THR
- Has nicotine addiction become a greater public health crisis than smoking
Chair
- Prof Thomas J. Glynn, PhD Adjunct Lecturer - Stanford Prevention Research Centre, Stanford University School of Medicine
Session Responder
Skip Murray Volunteer - Public Health Advocate
Speakers
- Prof Lion Shahab Professor of Health Psychology & Head of Research - Department of Behavioural Science and Health, University College London (UCL)
- Prof Neal L. Benowitz MD Professor of Medicine Emeritus (Active) - University of California, San Franciso
- Dr Jamie Hartmann-Boyce Assistant Professor in Health Promotion and Policy - University of Massachusetts Amherst
- Prof Scott Sherman Professor of Population Health, Medicine and Psychiatry - NYU Grossman School of Medicine
- Prof Megan Piper, PhD Professor, Division of General Internal Medicine, Department of Medicine - University of Wisconsin Madison
3:25 pm - 3:45 pm
PM REFRESHMENT BREAK
TOBACCO, NICOTINE & PUBLIC HEALTH CHALLENGES
3:45 pm - 4:00 pm
Health and economic implications of a nicotine product standard
Combustible tobacco smoking is becoming increasingly concentrated among individuals with mental health conditions, coinciding with a growing mental health crisis among youth and young adults. Efforts to achieve the tobacco endgame in the United States must also address populations with behavioral health comorbidities. The FDA has proposed a rule to reduce nicotine levels in cigarettes, but the long-term implications of this product standard for economic costs and tobacco-related health disparities remain uncertain.
This presentation will draw on findings from the Major Depression, Smoking, and E-Cigarettes (MDSE) microsimulation model to evaluate the health and economic outcomes of a nicotine reduction strategy for both the general U.S. population and individuals with major depression. The MDSE model integrates e-cigarette transition data from the Population Assessment on Tobacco and Health (PATH) study, smoking parameters from the Cancer Intervention and Surveillance Modeling Network, and data from the 2005–2023 National Survey on Drug Use and Health (NSDUH). It simulates prevalence, mortality, healthcare costs, productivity, and consumer expenditures under a baseline scenario. These outcomes are then evaluated under a reduced nicotine cigarette (RNC) policy scenario, using best- and worst-case estimates of the policy’s anticipated effects on future vaping, smoking, and product switching.
Findings highlight how the relationship between tobacco use and major depression shapes population health outcomes and influences the projected health and economic benefits of policy intervention.
Speaker
Asst Prof Jamie Tam, PhD, MPH Assistant Professor of Public Health (Health Policy) - Yale School of Public Health
4:00 pm - 4:15 pm
Four completely different kinds of evidence that vaping increases adult smoking cessation
While a contentious debate persists within the tobacco control community as to whether vaping decreases cigarette smoking, those supporting the affirmative side of the debate have the unusual good fortune of being able to draw on four completely different kinds of evidence in support of their position. These include (i) randomized controlled trials, (ii) population studies (including analyses of population-wide aggregated data and individual-level survey data); (iii) market behavior (including cigarette and e-cigarette sales data and stock market reactions); and (iv) economic studies finding that vaping and cigarette smoking are substitutes (some noting unintended adverse consequences of policies intended primarily to reduce youth vaping). This presentation will highlight the implication of having such diverse types of evidence all sharing the same conclusion about vaping’s impact on smoking cessation. Additionally, the presentation will examine the strengths and limitations of these bodies of evidence
Speaker
Prof Ken Warner Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus - School of Public Health, University of Michigan
4:15 pm - 4:30 pm
Strengthening the Evidence: Triangulation, replication, and the role of e-cigarettes in smoking cessation
Replication of studies is important, but triangulating data sources provides stronger evidence. Both replication and triangulation are crucial for building robust evidence on the effectiveness and acceptability of e-cigarettes for smoking cessation. Current research from various study designs shows that nicotine-containing e-cigarettes help adults who smoke to quit successfully and maintain abstinence. Emerging evidence also suggests that e-cigarettes are acceptable among individuals facing social disadvantages. However, there is ongoing debate about their role among young people. Using triangulation models, this talk will evaluate the strength of evidence for e-cigarette use among adults compared with young people.
Speaker
Dr Sharon Cox Principal Research Fellow, Tobacco and Alcohol Research Group - University College London (UCL)
4:30 pm - 4:45 pm
The Past is Prologue: Why bad health effects research leads to bad policy decisions
During this talk, Dr Steve Cook will discuss how many of the methodological problems found in cross-sectional studies on the health effects of e-cigarette use are at risk of being repeated for any nicotine or tobacco product marketed as a ‘safer alternative’ to cigarettes. Using nationally representative cross-sectional data from Wave 7 of the Population of Tobacco and Health (PATH) Study from the United States, Dr Cook will provide an example of a seemingly robust but spurious association between oral nicotine pouches and chronic obstructive pulmonary disease (COPD) and will discuss why all cross-sectional health effects studies should be interpreted with extreme caution unless they examine dose-response relationships and account for temporality and cigarette smoking confounding. The session will conclude by emphasizing the importance of developing a best practice framework to ensure that poorly constructed health effects research doesn’t lead to bad tobacco regulatory decision-making.
Speaker
Dr Steve Cook, PhD Assistant Research Scientist, School of Public Health Epidemiology - University of Michigan
4:45 pm - 5:00 pm
Closing Keynote: Finding a path forward during disruption
On the heels of remarkable progress in reducing cigarette smoking, we face potential threats to continued success. These threats are multifaceted and multisectorial, and we are now in an era of volatility and disruption. In the face of this shifting landscape, our familiar strategies and instincts may need to be rethought. This presentation will explore what core strategies we may need to change, which ones stay true, and a potential path forward. Both the tobacco marketplace and the context of regulation in the U.S. are changing. Thus, as scientists and a field dedicated to reducing the tremendous toll from combustible tobacco use, we need to adapt and mobilize to meet these new challenges. This presentation will highlight pillars of an approach for moving forward.
Speaker
- Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
5:00 pm - 5:20 pm
Panel Discussion and Q&A
Tobacco, Nicotine & Public Health
- Is nicotine dependence per se a public health priority
- Can we address or research the smoking crisis without discussing health inequalities and economic disparities
- Has the recent focus on nicotine and addiction created a confusing message for current smokers
Chair
- Prof Thomas J. Glynn, PhD Adjunct Lecturer - Stanford Prevention Research Centre, Stanford University School of Medicine
Speakers
- Asst Prof Jamie Tam, PhD, MPH Assistant Professor of Public Health (Health Policy) - Yale School of Public Health
- Prof Ken Warner Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus - School of Public Health, University of Michigan
- Dr Sharon Cox Principal Research Fellow, Tobacco and Alcohol Research Group - University College London (UCL)
- Dr Steve Cook, PhD Assistant Research Scientist, School of Public Health Epidemiology - University of Michigan
- Prof Robin Mermelstein Distinguished Professor of Psychology and IHRP Director - University of Illinois, Chicago
5:30 pm - 6:30 pm
